In the most recent trading session, Hercules Capital (HTGC) closed at $17.54, indicating a +1.8% shift from the previous trading day.
In the most recent trading session, Hercules Capital (HTGC) closed at $16.83, indicating no shift from the previous trading day.
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Hercules Capital (HTGC) closed at $19.06 in the latest trading session, marking a -0.21% move from the prior day.
Hercules Capital (HTGC) reachead $19.32 at the closing of the latest trading day, reflecting a +0.42% change compared to its last close.
Hercules Capital is one of the best BDC with a 20-year history, offering a 10.4% dividend yield and a +1,040% total return since inception. HTGC's strong financials, including recent record-high TII and NII, ensure sustainable dividends and long-term stability. The recent 19% pullbacks give a decent buy signal, despite the stock's premium P/NAV valuation.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Hercules Capital offers a compelling buy-the-dip opportunity for income investors with a 10% dividend yield and strong earnings yield. HTGC's internally managed structure enhances shareholder alignment and cost efficiency, supporting consistently high returns and a high-quality, predominantly first-lien portfolio. Despite recent market volatility, HTGC maintains low non-accrual rates, strong dividend coverage, conservative leverage, and robust liquidity.
The latest trading day saw Hercules Capital (HTGC) settling at $18.84, representing a +1.78% change from its previous close.
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a rating of BBB+ to Hercules Capital, Inc.'s (NYSE: HTGC or “the company”) $250 million 4.75% convertible unsecured notes due September 2028. The rating Outlook is Stable. Key Credit Considerations The rating reflects the company's diversified $3.66 billion investment portfolio consisting of 118 portfolio companies (debt investments) with a focus on senior secured first lien venture debt investments (86.9%) in the technology and life sciences sectors, sol.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has agreed to sell to the initial purchasers in a private offering, $250.0 million aggregate principal amount of its 4.75% Convertible Unsecured Notes due 2028 (the “Convertible Notes”). The Company also has granted the initial purchasers an option to purchase up to an additional $37.5 million principal amount of the Convertible Notes to cover overallotments, if any. Th.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it plans to make an offering of $250.0 million aggregate principal amount of its Convertible Unsecured Notes due 2028 (the “Convertible Notes”). The Company plans to grant the initial purchasers an option to purchase up to an additional $37.5 million principal amount of the Convertible Notes to cover overallotments, if any. The Convertible Notes will be offered only to qua.